Cyclazodone, 4 Things Cops Should Know
1: What is Cyclazodone?
Cyclazodone is starting to pop up around the United States. It has the potential of becoming very popular in a very short amount of time, so it is important for cops to brush up on exactly what it is. Cyclazodone is a stimulant drug that was developed by the American Cyanamid Company in the 1960s. The drug is similar to other drugs like thozalinone or pemoline in terms of its effects. The patents found that Cyclazodone had properties that could reduce fatigue and help with weight loss. Cyclazonone is considered a Novel Psychoactive Substance, which are synthetic drugs becoming popular across the world.
2: What are the Effects of Cyclazodone?
The effects of cyclazodone include stimulation, focus enhancement, stamina enhancement, increased blood pressure, and mild euphoria. There are some anecdotal reports that suggest cyclazodone and its parent compound pemoline may have properties that are similar to central nervous system stimulants such as Ritalin and amphetamine.
Below is a list of signs and symptoms you may see when people use Cyclazodone.
Bruxism
3: What are the Risks of Cyclazodone?
Cyclazodone has not been documented to be used recreationally by humans before it appeared on the online research chemical market in 2017. Based on related compounds, it is speculated that it likely possesses hepatotoxic and other not-yet-known toxic properties.
The potential for addiction is a serious risk with heavy recreational stimulant use. The potential for self-administration and dependence is considered to be low for this compound as compared to other stimulants that work on the dopamine system.
Repeated use of cyclazodone leads to tolerance of its effects, which requires users to take increasingly large doses to achieve the same results. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).
Aside from the fact that this chemical is similar to other stimulants, it is likely that the misuse of this compound may cause a state of psychosis, which is characterized by a variety of symptoms, (e.g., paranoia, hallucinations, or delusions. In a review of the treatments for amphetamine and methamphetamine abuse-induced psychosis, the authors found that 5–15% of users did not recover fully. In this same review, it is reported that at least one trial found that antipsychotic medications effectively relieved the symptoms of acute amphetamine psychosis. Psychosis is a very rare occurrence when people are given therapeutic help. When combined with sleep deprivation, prolonged use of high doses of stimulants increases the risk of experiencing a psychotic episode.
Section 4: What are the Legal Status of Cyclazodone?
Cyclazodone is a gray area compound that is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances. It is a banned stimulant under the World Anti-Doping Agency prohibited list.
Germany: Cyclazodone is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). However, it is considered a medicine under §2 AMG (Medicines Act), which was declared ineffective by a decision of the European Court of Justice. As a result, Cyclazodone can be considered legal.
Switzerland: Cyclazodone is not controlled under Buchstabe A, B, C and D. It is not considered illegal.
United States: Cyclazodone is structurally similar to pemoline, a Schedule IV controlled substance in the US. Therefore, it may fall under Federal Analogue Act, 21 U.S.C. § 813 when intended for human consumption.
References for This Article
^ US 3321470, Howell Jr CF, Hardy RA, Quinones N, "5-Arylidene-2-Amino-2-Oxazolin-4-Ones", issued 23 May 1967, assigned to American Cyanamid
^ Jump up to:a b US 3609159, De Marne V, Pierre D, Guidicelli RL, Najer H, "5-Phenyl-2-Cyclopropylamino-4-Oxazolinone", issued 28 September 1971, assigned to Les Laboratoires Dausse
^ GB 1005738, De Marne V, Pierre D, Guidicelli RL, Najer H, "5-Phenyl-2-Cyclopropylamino-4-Oxazolinone", issued 29 September 1965, assigned to Les Laboratoires Dausse
^ Greenblatt EN, Osterberg AC (July 1965). "Some pharmacologic properties of thozalinone, a new excitant". Toxicology and Applied Pharmacology. 7 (4): 566–78. doi:10.1016/0041-008x(65)90042-6. PMID 4378772.
^ "World Anti-Doping Agency 2008 Prohibited List" (PDF). World Anti-Doping Agency. 22 September 2007.
